Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
Reading Time: 7 minutes Zug, Switzerland: Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology, showing the trial met all primary and key secondary endpoints1
Notice to attend the extraordinary general meeting in OssDsign AB
Reading Time: 29 minutes The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the extraordinary general meeting at 10:00 am on Wednesday 18 December 2024 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30
28th World Investment Conference in Riyadh Concludes with Calls for International Collaboration, Innovation, and Sustainability
Reading Time: 3 minutes Riyadh, Saudi Arabia: International collaboration, innovation and sustainability were the key themes of the 28th World Investment Conference (WIC28), hosted by Invest Saudi and The World Association of Investment Promotion Agencies (WAIPA) that concluded in Riyadh this week.
#24-409 Listing of Derivatives at NGM
Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024
Reading Time: < 1 minute Stock Exchange Release 28.11.2024 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024 Date 28.11.2024 Exchange transaction Buy Share class FSKRS Amount 300 Average price/share 14.8196 EUR Highest price/share 14.8200 EUR Lowest price/share
The board of Peptonic resolves, subject to the approval a subsequent general meeting, on a rights issue of units of approximately SEK 26.5 million
Reading Time: 9 minutes NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE
STENOCARE Celebrates Denmark’s Permanent Legalisation of Medical Cannabis
Reading Time: 2 minutes STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO Today, the Danish parliament formally agreed on permanent legalisation of medical cannabis. This is fantastic news for both Danish patients and Stenocare, as it ensures continued access to and the sale of medical cannabis
SyntheticMR resolves on a rights issue of approximately SEK 65 million
Reading Time: 12 minutes THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PEPTONIC MEDICAL AB
Reading Time: 11 minutes N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall
Inside information, profit warning: Fondia Plc lowers its guidance on the outlook for 2024
Reading Time: < 1 minute Fondia Plc Company release, inside information 28.11.2024 at 10.10 p.m. EET Fondia lowers its outlook published on September 11, 2024, on net sales and operating profit for 2024 due to the continued difficult and uncertain market situation. The signs of